Yang Z.L.,CAS Kunming Institute of Botany
A brief survey towards an understanding of evolution of Basidiomycota in the last five decades is given. Between 1960-1990 studies were based mainly on morphology, subcellular structure, biochemistry, physiology and ecology. In the last 20 years, molecular methods have revolutionized the study of taxonomy, systematics, phylogeny, biogeography, population and microevolutionary processes in basidiomycetes. A fundamental improvement in the understanding of evolution of basidiomycetes has been achieved. It is anticipated that numerous new taxa at different taxonomic levels will be recognized based on integrated approaches, and new data will soon provide fascinating insights into the origin, evolution and biogeography of basidiomycetes in the coming years. © The Author(s) 2011. Source
CAS Kunming Institute of Botany, Shangahi Institutes For Biological Science and Chinese Academy of Sciences | Date: 2014-02-28
The present invention relates to the pharmaceutical field, in particular to a phenanthridine derivative as shown in general formula (1) a pharmaceutical composition comprising the derivative, its preparation method, and its uses in manufacture of a medicament for the prevention or treatment of a disease related to the activity of Wnt signaling pathway, hepatitis C and hepatitis B.
CAS Kunming Institute of Botany and New York University | Date: 2014-01-29
Disclosed are heterocyclo compounds that have a formula represented by the following: and wherein X, R
CAS Kunming Institute of Botany | Date: 2013-12-20
Provided are a low-molecular-weight fucosylated glycosaminoglycan derivative (derivative of Low molecular weight Fucosylated Glycosaminoglycan, dLFG) having anticoagulant activity, a preparation method thereof, a pharmaceutical composition comprising dLFG or a pharmaceutically acceptable salt thereof, and the use of dLFG and pharmaceutical composition thereof in preparing medicine for treating thrombotic diseases.
Southern Medical University and CAS Kunming Institute of Botany | Date: 2014-11-03
The invention relates to a use of an urushiol compound (code named GQ-5) in preparation of pharmaceutical compositions for inhibiting Smad3 phosphorylation. We verify that GQ-5 inhibited the interaction of Smad3 with TGF- type I receptor (TRI), inhibited subsequent phosphorylation of Smad3, reduced nuclear translocation of Smads complex, and suppressed the transcription of major fibrotic genes such as -smooth muscle actin (-SMA), collagen I and fibronectin. Therefore, GQ-5 could be a potent and selective inhibitor of TGF-1-induced Smad3 phosphorylation, and be used to prepare pharmaceutical compositions for inhibiting Smad3 phosphorylation.